+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adult Vaccines Market by Vaccine Type (Covid 19, Hepatitis, Herpes Zoster), Vaccine Technology (Conjugate, Dna, Inactivated), Route of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030- Product Image
Adult Vaccines Market by Vaccine Type (Covid 19, Hepatitis, Herpes Zoster), Vaccine Technology (Conjugate, Dna, Inactivated), Route of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030- Product Image
Sale

Adult Vaccines Market by Vaccine Type (Covid 19, Hepatitis, Herpes Zoster), Vaccine Technology (Conjugate, Dna, Inactivated), Route of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015023
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The adult vaccines market is undergoing rapid transformation, driven by demographic changes, evolving infectious disease threats, and an urgent focus on public health system resilience. Decision-makers are rethinking immunization strategies to capture growth opportunities, respond to policy developments, and ensure effective coverage amid a complex global landscape.

Market Snapshot: Adult Vaccines Market Outlook and Growth

The Adult Vaccines Market grew from USD 19.11 billion in 2024 to USD 20.77 billion in 2025. It is expected to continue growing at a CAGR of 8.27%, reaching USD 30.80 billion by 2030. This expansion is fueled by ongoing innovation in vaccine modalities and increasing prioritization of immunization for aging and at-risk adult populations, with sustained momentum from both public and private sector investments.

Scope & Segmentation: Depth and Breadth of Coverage

This report analyzes the adult vaccines market across critical dimensions to provide a detailed view for senior decision-makers:

  • Vaccine Types: COVID-19 (Inactivated, mRNA, Protein Subunit, Viral Vector), Hepatitis (Combined, Hepatitis A, Hepatitis B), Herpes Zoster (Shingrix, Zostavax), HPV (9-Valent, Bivalent, Quadrivalent), Meningococcal (MenACWY, MenB), MMR, Pandemic Influenza, Pneumococcal (PCV13, PCV15, PCV20, PPSV23), Seasonal Influenza, Tdap (Td, Tdap), and Varicella.
  • Vaccine Technologies: Conjugate (Polysaccharide Conjugate), DNA (Gene Encoded, Plasmid DNA), Inactivated, Live Attenuated, mRNA (Nucleoside Modified, Self Amplifying), Recombinant (Subunit), Toxoid (Diphtheria, Tetanus), and Viral Vector (Non Replicating, Replicating).
  • Routes of Administration: Intradermal, Intramuscular, Intranasal, Oral, Subcutaneous.
  • Distribution Channels: Clinics, Hospitals, Online Pharmacies, Public Health Centers, Retail Pharmacies.
  • Age Groups: 18–30, 31–45, 46–60, 61 and above.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Moderna, Inc., Johnson & Johnson, CSL Limited, Novavax, Inc., Bavarian Nordic A/S, Valneva SE.

Key Takeaways: Strategic Insights for Decision-Makers

  • Rapid scientific advances in molecular immunology and vaccine technology, such as mRNA and viral vector platforms, are reshaping adult immunization and enabling faster responses to emerging threats.
  • Changing regulatory frameworks, including expedited approval processes and post-marketing surveillance, drive stronger collaboration between public agencies and the pharmaceutical industry.
  • Regional strategies reflect local priorities—including domestic manufacturing in Asia-Pacific, regulatory harmonization in EMEA, and digital access models in the Americas—requiring tailored approaches for each market.
  • Supply chain resilience has become a crucial differentiator as organizations adapt sourcing, manufacturing, and distribution in response to new trade and tariff environments.
  • Personalized outreach and flexible delivery models are vital to increase vaccine uptake among varied age groups and across multiple channels, addressing both urban and rural access challenges.

Tariff Impact: Navigating Trade Policy Changes

Forthcoming U.S. tariff adjustments are adding complexity to international vaccine supply chains. Manufacturers are proactively diversifying production locations and logistics partners to offset duty-driven cost increases and potential delivery delays. These changes emphasize the need for robust procurement and inventory strategies to sustain reliable market access.

Methodology & Data Sources

The adult vaccines market analysis is built on rigorous secondary research from scholarly publications, regulatory filings, and open-source repositories. Targeted expert interviews with biopharmaceutical executives, supply chain professionals, and health policymakers provide timely qualitative insights, while systematic triangulation with quantitative metrics ensures accuracy and relevance.

Why This Report Matters: Actionable Intelligence for Leadership

  • Enables strategic planning by highlighting technology-driven shifts and policy developments that impact competitive positioning and growth prospects.
  • Delivers in-depth segmentation and regional analyses, supporting targeted resource allocation and market-entry decisions.
  • Offers practical insights for enhancing supply chain resilience, operational flexibility, and stakeholder collaboration as market conditions evolve.

Conclusion

The adult vaccines market demands adaptive leadership in the face of industry innovation and shifting global dynamics. Senior decision-makers can use these insights to optimize operations, strengthen partnerships, and build future-ready immunization programs.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of mRNA vaccine technology for influenza and RSV in adults with enhanced immunogenicity
5.2. Rising demand for combination vaccines targeting multiple adult diseases in a single administration format
5.3. Expansion of adult pneumococcal vaccine recommendations in immunocompromised and elderly patient populations
5.4. Growth of digital health platforms leveraging AI to track adult vaccination adherence and personalized reminders
5.5. Emergence of customized vaccination schedules based on genetic profiling and lifestyle-related risk assessments
5.6. Strategic partnerships between biopharma companies to accelerate clinical development of next-generation adult vaccines
5.7. Impact of recent regulatory approvals for novel respiratory syncytial virus vaccines in older adult cohorts
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Adult Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. COVID-19
8.2.1. Inactivated
8.2.2. Mrna
8.2.3. Protein Subunit
8.2.4. Viral Vector
8.3. Hepatitis
8.3.1. Combined
8.3.2. Hepatitis A
8.3.3. Hepatitis B
8.4. Herpes Zoster
8.4.1. Shingrix
8.4.2. Zostavax
8.5. Hpv
8.5.1. 9-Valent
8.5.2. Bivalent
8.5.3. Quadrivalent
8.6. Meningococcal
8.6.1. MenACWY
8.6.2. MenB
8.7. Mmr
8.8. Pandemic Influenza
8.9. Pneumococcal
8.9.1. Pcv13
8.9.2. Pcv15
8.9.3. Pcv20
8.9.4. Ppsv23
8.10. Seasonal Influenza
8.11. Tdap
8.11.1. Td
8.11.2. Tdap
8.12. Varicella
9. Adult Vaccines Market, by Vaccine Technology
9.1. Introduction
9.2. Conjugate
9.2.1. Polysaccharide Conjugate
9.3. Dna
9.3.1. Gene Encoded
9.3.2. Plasmid Dna
9.4. Inactivated
9.5. Live Attenuated
9.6. Mrna
9.6.1. Nucleoside Modified
9.6.2. Self Amplifying
9.7. Recombinant
9.7.1. Subunit
9.8. Toxoid
9.8.1. Diphtheria Toxoid
9.8.2. Tetanus Toxoid
9.9. Viral Vector
9.9.1. Non Replicating
9.9.2. Replicating
10. Adult Vaccines Market, by Route Of Administration
10.1. Introduction
10.2. Intradermal
10.3. Intramuscular
10.4. Intranasal
10.5. Oral
10.6. Subcutaneous
11. Adult Vaccines Market, by Distribution Channel
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Online Pharmacies
11.5. Public Health Centers
11.6. Retail Pharmacies
12. Adult Vaccines Market, by Age Group
12.1. Introduction
12.2. 18 To 30
12.3. 31 To 45
12.4. 46 To 60
12.5. 61 And Above
13. Americas Adult Vaccines Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Adult Vaccines Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Adult Vaccines Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. GlaxoSmithKline plc
16.3.3. Merck & Co., Inc.
16.3.4. Sanofi S.A.
16.3.5. Moderna, Inc.
16.3.6. Johnson & Johnson
16.3.7. CSL Limited
16.3.8. Novavax, Inc.
16.3.9. Bavarian Nordic A/S
16.3.10. Valneva SE
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ADULT VACCINES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ADULT VACCINES MARKET: RESEARCHAI
FIGURE 26. ADULT VACCINES MARKET: RESEARCHSTATISTICS
FIGURE 27. ADULT VACCINES MARKET: RESEARCHCONTACTS
FIGURE 28. ADULT VACCINES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ADULT VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID-19, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY COMBINED, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ADULT VACCINES MARKET SIZE, BY SHINGRIX, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ADULT VACCINES MARKET SIZE, BY ZOSTAVAX, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ADULT VACCINES MARKET SIZE, BY 9-VALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ADULT VACCINES MARKET SIZE, BY BIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ADULT VACCINES MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ADULT VACCINES MARKET SIZE, BY MENACWY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ADULT VACCINES MARKET SIZE, BY MENB, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ADULT VACCINES MARKET SIZE, BY MMR, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ADULT VACCINES MARKET SIZE, BY PANDEMIC INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV13, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV15, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ADULT VACCINES MARKET SIZE, BY PCV20, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ADULT VACCINES MARKET SIZE, BY PPSV23, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ADULT VACCINES MARKET SIZE, BY SEASONAL INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ADULT VACCINES MARKET SIZE, BY TD, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ADULT VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE CONJUGATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ADULT VACCINES MARKET SIZE, BY GENE ENCODED, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ADULT VACCINES MARKET SIZE, BY PLASMID DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ADULT VACCINES MARKET SIZE, BY NUCLEOSIDE MODIFIED, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ADULT VACCINES MARKET SIZE, BY SELF AMPLIFYING, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ADULT VACCINES MARKET SIZE, BY DIPHTHERIA TOXOID, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ADULT VACCINES MARKET SIZE, BY TETANUS TOXOID, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL ADULT VACCINES MARKET SIZE, BY NON REPLICATING, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL ADULT VACCINES MARKET SIZE, BY REPLICATING, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL ADULT VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL ADULT VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL ADULT VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL ADULT VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL ADULT VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 161. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY REGION, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL ADULT VACCINES MARKET SIZE, BY 18 TO 30, BY REGION, 2025-2030 (USD MILLION)
TABLE 165. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY REGION, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL ADULT VACCINES MARKET SIZE, BY 31 TO 45, BY REGION, 2025-2030 (USD MILLION)
TABLE 167. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY REGION, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL ADULT VACCINES MARKET SIZE, BY 46 TO 60, BY REGION, 2025-2030 (USD MILLION)
TABLE 169. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL ADULT VACCINES MARKET SIZE, BY 61 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 208. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 247. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 248. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 249. CANADA ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 250. CANADA ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 251. CANADA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 252. CANADA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 253. CANADA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 254. CANADA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 255. CANADA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 256. CANADA ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 257. CANADA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 258. CANADA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 259. CANADA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 260. CANADA ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 261. CANADA ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 262. CANADA ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 263. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 264. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 265. CANADA ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 266. CANADA ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 267. CANADA ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 268. CANADA ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 269. CANADA ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 270. CANADA ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 271. CANADA ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 272. CANADA ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 273. CANADA ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 274. CANADA ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 275. CANADA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 276. CANADA ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 277. CANADA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 278. CANADA ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 279. CANADA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. CANADA ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. CANADA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. CANADA ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 284. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 285. MEXICO ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 286. MEXICO ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 287. MEXICO ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 288. MEXICO ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 289. MEXICO ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 290. MEXICO ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 291. MEXICO ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 292. MEXICO ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 293. MEXICO ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 294. MEXICO ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 295. MEXICO ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 296. MEXICO ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 297. MEXICO ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 298. MEXICO ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 299. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 300. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 301. MEXICO ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 302. MEXICO ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 303. MEXICO ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 304. MEXICO ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 305. MEXICO ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 306. MEXICO ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 307. MEXICO ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 308. MEXICO ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 309. MEXICO ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 310. MEXICO ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 311. MEXICO ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 312. MEXICO ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 313. MEXICO ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. MEXICO ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. MEXICO ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. MEXICO ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. MEXICO ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 318. MEXICO ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 319. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 320. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 321. BRAZIL ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 322. BRAZIL ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 323. BRAZIL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 324. BRAZIL ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 325. BRAZIL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 326. BRAZIL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 327. BRAZIL ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 328. BRAZIL ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 329. BRAZIL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 330. BRAZIL ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLION)
TABLE 331. BRAZIL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2018-2024 (USD MILLION)
TABLE 332. BRAZIL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL, 2025-2030 (USD MILLION)
TABLE 333. BRAZIL ADULT VACCINES MARKET SIZE, BY TDAP, 2018-2024 (USD MILLION)
TABLE 334. BRAZIL ADULT VACCINES MARKET SIZE, BY TDAP, 2025-2030 (USD MILLION)
TABLE 335. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 336. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 337. BRAZIL ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2018-2024 (USD MILLION)
TABLE 338. BRAZIL ADULT VACCINES MARKET SIZE, BY CONJUGATE, 2025-2030 (USD MILLION)
TABLE 339. BRAZIL ADULT VACCINES MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 340. BRAZIL ADULT VACCINES MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 341. BRAZIL ADULT VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
TABLE 342. BRAZIL ADULT VACCINES MARKET SIZE, BY MRNA, 2025-2030 (USD MILLION)
TABLE 343. BRAZIL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 344. BRAZIL ADULT VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 345. BRAZIL ADULT VACCINES MARKET SIZE, BY TOXOID, 2018-2024 (USD MILLION)
TABLE 346. BRAZIL ADULT VACCINES MARKET SIZE, BY TOXOID, 2025-2030 (USD MILLION)
TABLE 347. BRAZIL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
TABLE 348. BRAZIL ADULT VACCINES MARKET SIZE, BY VIRAL VECTOR, 2025-2030 (USD MILLION)
TABLE 349. BRAZIL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 350. BRAZIL ADULT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 351. BRAZIL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 352. BRAZIL ADULT VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 353. BRAZIL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 354. BRAZIL ADULT VACCINES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 355. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 356. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 357. ARGENTINA ADULT VACCINES MARKET SIZE, BY COVID-19, 2018-2024 (USD MILLION)
TABLE 358. ARGENTINA ADULT VACCINES MARKET SIZE, BY COVID-19, 2025-2030 (USD MILLION)
TABLE 359. ARGENTINA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2018-2024 (USD MILLION)
TABLE 360. ARGENTINA ADULT VACCINES MARKET SIZE, BY HEPATITIS, 2025-2030 (USD MILLION)
TABLE 361. ARGENTINA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2018-2024 (USD MILLION)
TABLE 362. ARGENTINA ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, 2025-2030 (USD MILLION)
TABLE 363. ARGENTINA ADULT VACCINES MARKET SIZE, BY HPV, 2018-2024 (USD MILLION)
TABLE 364. ARGENTINA ADULT VACCINES MARKET SIZE, BY HPV, 2025-2030 (USD MILLION)
TABLE 365. ARGENTINA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2018-2024 (USD MILLION)
TABLE 366. ARGENTINA ADULT VACCINES MARKET SIZE, BY MENINGOCOCCAL, 2025-2030 (USD MILLIO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Adult Vaccines market report include:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Moderna, Inc.
  • Johnson & Johnson
  • CSL Limited
  • Novavax, Inc.
  • Bavarian Nordic A/S
  • Valneva SE

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 20.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 30.8 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Adult Vaccine Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Adult Vaccine Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Adult Vaccines Market Report 2025 - Product Image

Adult Vaccines Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Adult Vaccines - Global Strategic Business Report - Product Image

Adult Vaccines - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Adult Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Adult Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Vaccines Market by Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA Vaccines), Product Type (BCG, COVID-19, DPTa), Vaccine Combination, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2025-2030 - Product Image

Vaccines Market by Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA Vaccines), Product Type (BCG, COVID-19, DPTa), Vaccine Combination, Vaccine Classification, Route of Administration, Dosage, Age Group, End User - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.